EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Pediatric patients with von Hippel–Lindau and hemangioblastomas treated successfully with belzutifan

Emily Duan iD, Michael Robinson, Charles Davis, Sumit Pruthi, Christina Shin, Marisa Lewis, Julian A Martinez-Agosto, Michael B Gorin, Brian M Shuch, Debra L Friedman, Vivian Y Chang

Pediatric Blood & Cancer · 2025-01 · 72 (1)

DOI: 10.1002/pbc.31371 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 16.10.2024. Verfasst von Emily Duan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California, Los Angeles (UCLA), Los Angeles, California, USA. Hauptthemen laut MEDLINE: Hemangioblastoma, von Hippel-Lindau Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hemangioblastoma is the most common tumor associated with von Hippel–Lindau (VHL), and are a leading cause of mortality. We present five pediatric patients with VHL‐associated hemangioblastomas treated with belzutifan, a hypoxia‐inducible factor 2a (HIF2a) inhibitor. Three patients were started on belzutifan due to vision loss from progressive retinal hemangioblastomas. Within one year of treatment, all three patients had improvement in hemangioblastoma size and visual acuity. For patients with intracranial lesions, belzutifan resulted in an improvement in neurologic symptoms and hemangioblastoma size. Four patients experienced grade 1–2 anemia and two patients required a dose reduction. Our report suggests that belzutifan can be an effective therapy for pediatric, adolescent, and young adult patients with VHL‐associated hemangioblastomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemangioblastomavon Hippel-Lindau DiseaseHumansCerebellar NeoplasmsEndothelial PAS Domain-Containing Protein 1

Stichwörter der Autor:innen

belzutifanhemangioblastomapediatricvon Hippel–Lindau

Substanzen

Endothelial PAS Domain-Containing Protein 1

Autor:innen und Institutionen

  • Department of Pediatrics, University of California, Los Angeles (UCLA), Los Angeles, California, USA.
  • Division of Pediatric Hematology/Oncology, Vanderbilt, Nashville, Tennessee, USA.
  • Department of Radiology, UCLA, Los Angeles, California, USA.
  • Department of Neuroradiology, Vanderbilt, Nashville, Tennessee, USA.
  • Ronald Reagan UCLA Medical Center, UCLA, Los Angeles, California, USA.
  • Division of Pediatric Hematology/Oncology, UCLA, Los Angeles, California, USA.

ORCID-Profile: Emily Duan

Zitieren

APA

Duan, E., Robinson, M., Davis, C., Pruthi, S., Shin, C., Lewis, M., Martinez-Agosto, J. A., Gorin, M. B., Shuch, B. M., Friedman, D. L., & Chang, V. Y. (2025). Pediatric patients with von Hippel–Lindau and hemangioblastomas treated successfully with belzutifan. Pediatric Blood & Cancer, 72(1). https://doi.org/10.1002/pbc.31371

Vancouver

Duan E, Robinson M, Davis C, Pruthi S, Shin C, Lewis M, et al. Pediatric patients with von Hippel–Lindau and hemangioblastomas treated successfully with belzutifan. Pediatric Blood & Cancer. 2025;72(1). doi:10.1002/pbc.31371

BibTeX
@article{Duan2025,
  author = {Duan, Emily and Robinson, Michael and Davis, Charles and Pruthi, Sumit and Shin, Christina and Lewis, Marisa and Martinez-Agosto, Julian A and Gorin, Michael B and Shuch, Brian M and Friedman, Debra L and Chang, Vivian Y},
  title = {Pediatric patients with von Hippel–Lindau and hemangioblastomas treated successfully with belzutifan},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  volume = {72},
  number = {1},
  doi = {10.1002/pbc.31371}
}
Kostenlos starten →